Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence
CD38 expression on myeloma cells is a important issue affecting the early response to the anti-CD38 antibody daratumumab. Nevertheless, elements affecting CD38 expression in untreated a number of myeloma are usually not totally elucidated. On this research, we discovered that CD38 expression was considerably decrease in myeloma sufferers with the translocation t(11;14)-associated immature plasma cell phenotype, and significantly in these expressing B-cell-associated genes comparable to PAX5 and CD79A. CD138, a consultant marker of plasmacytic differentiation, was additionally considerably decrease in these sufferers, suggesting that CD38 expression could also be related to the differentiation and maturation phases of myeloma cells.
Moreover, the BCL2/BCL2L1 ratio, a response marker of the BCL2 inhibitor venetoclax, was considerably larger in sufferers with the immature phenotype expressing B-cell-associated genes. The BCL2/BCL2L1 ratio and CD38 expression had been considerably negatively correlated. We additionally confirmed that sufferers with translocation t(11;14) expressing B-cell-associated genes had been certainly much less delicate to daratumumab-mediated direct cytotoxicity however extremely delicate to venetoclax therapy in ex vivo assays. Furthermore, all-trans-retinoic acid, which boosts CD38 expression and induces cell differentiation in myeloma cells, diminished B-cell marker expression and the BCL2/BCL2L1 ratio in myeloma cell traces, resulting in diminished efficacy of venetoclax.
Venetoclax particularly induces cell dying in myeloma with t(11;14), though why sufferers with translocation t(11;14) present BCL2 dependence is unclear. These outcomes counsel that BCL2 dependence, in addition to CD38 expression, are deeply related to the differentiation and maturation phases of myeloma cells. This research highlights the significance of analyzing t(11;14) and contemplating cell maturity in myeloma therapy methods.
Key phrases: BCL2; CD38; daratumumab; a number of myeloma; venetoclax.
CD142 performs a key position within the carcinogenesis of gastric adenocarcinoma by inhibiting BCL2-dependent autophagy
CD142 is expressed on the floor of a number of malignant tumors and contributes to varied carcinogenesis. Nevertheless, the position of CD142 within the pathogenesis of GAC stays unclear. This research aimed to analyze the position of CD142 in GAC carcinogenesis. Our outcomes confirmed that CD142 expression was considerably elevated in GAC most cancers tissues, particularly in these with vital invasion or metastasis. The invasion and migration of CD142-positive SNU16 cells had been considerably elevated in contrast with these of CD142-negative cells. Furthermore, CD142 overexpression promoted the invasion and migration of SGC083 cells, however CD142 silencing was opposite. As well as, there was a constructive correlation between CD142 expression of most cancers tissues and serum IL-Eight ranges. CD142 overexpression promotes IL-Eight manufacturing in SGC083 cells.
In vivo evaluation confirmed that the implantation of CD142-positive SNU16 cells promoted the expansion of xenograft tumor and the manufacturing of IL-8. Mechanistically, CD142 silencing not solely inhibited the expression of BCL2 and the interplay between BCL2 and Beclin1, but additionally promoted the autophagic response in SGC083. Moreover, CD142 silencing-induced IL-Eight degradation was recovered by therapy of autophagy inhibitor 3-MA. CD142 can inhibit autophagic cell dying and the autophagic degradation of IL-Eight in GAC, which exerts an efficient impact on GAC carcinogenesis.
The Incidence and Remedy Response of Double Expression of MYC and BCL2 in Sufferers with Diffuse Giant B-Cell Lymphoma: A Systematic Evaluate and Meta-Evaluation
MYC/BCL2 protein co-expression (i.e., double expressor) has been proven to be a unfavorable predictor of consequence in diffuse massive B-cell lymphoma (DLBCL). We aimed to determine the incidence of double expressor standing in sufferers with de novo DLBCL and determine the predictive worth of this biomarker on therapy response by way of systematic evaluate and meta-analysis. PubMed and Embase had been looked for research printed by way of December 2019 that reported proportions of double expressor DLBCL. The pooled proportions of MYC and BCL2 expression, each alone and together, had been computed utilizing the inverse variance technique for calculating weights and by the DerSimonian-Laird technique. The pooled odds ratios (ORs) of full remission (CR) fee had been calculated, and meta-regression evaluation was carried out to discover heterogeneity. Forty-one research (7054 sufferers) had been included.
The pooled incidence of double expressor standing in DLBCL was 23% (95% confidence interval [CI], 20-26%), with an adjusted estimate of 31% (95% CI, 27-36%). Neither MYC/BCL2 protein cutoff values, race, imply, or median age of included sufferers, or total research high quality was a big issue of heterogeneity (p ≥ 0.20). Instances with out double expressor standing demonstrated the next likelihood of CR to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy (OR, 2.69; 95% CI, 1.55-4.67). Our outcomes reaffirm the predictive energy of this essential biomarker.
Key phrases: immunohistochemistry; lymphoma; meta-analysis; systematic evaluate.
Computational research on novel pure inhibitors focusing on BCL2
Very best lead compounds and candidate medication with inhibitory impact on BCL2 had been screened from ZINC database, which laid a basis for drug growth and compound enchancment of drug therapy for diffuse massive B-cell lymphoma (DLCBL). Identification of potential BCL2 inhibitors by computer-aided digital screening. Libdock was utilized to 17,931 compounds and the highest 20 had been chosen for additional evaluation. Chosen compounds had been carried out absorption, distribution, metabolism, and excretion (ADME) and toxicity prediction. The binding affinity between the chosen ligands and BCL2 was confirmed by Molecular docking.
- The brand new pure compounds, ZINC00000255131 and ZINC00013298233, had been discovered to bind intently with BCL2. Moreover, all of them scored decrease in ames-induced mutagenicity, rodent carcinogenicity, non-developmental toxicity potential, and cytochrome P4502D6 tolerance. Molecular dynamics simulation reveals that the mixtures of ZINC00000255131 and ZINC00013298233 with BCL2 within the pure surroundings are extra secure.
- Two new compounds, ZINC00000255131 and ZINC00013298233, had been discovered to be potential inhibitors of BCL2. These compounds have been proved to be secure, which is of nice significance for the event and enchancment of DLCBL medication.
Assembling BH3-mimic peptide right into a nanocluster to focus on intracellular Bcl2 in the direction of the apoptosis induction of most cancers cell
Bcl-2, an anti-apoptotic protein, is at all times overexpressed in tumor cells to suppress the pro-apoptotic perform of Bax, thereby prolonging the lifetime of tumor. Nevertheless, BH3 proteins may instantly activate Bax by way of antagonizing Bcl-2 to induce apoptosis in response to the stimulation. Thus, mimicking BH3 proteins with a peptide is a possible technique for anti-cancer remedy. Sadly, medical translation of BH3-mimic peptide is hindered by its inefficacious mobile internalization and proteolysis resistance.
Herein, we translated a BH3-mimic peptide right into a peptide-auric spheroidal nanocluster (BH3-AuNp), during which polymeric BH3-Auric precursors [Au1+-S-BH3]n are in-situ self-assembled on the floor of gold nanoparticles by a one-pot synthesis. Expectedly, this technique may enhance the anti-proteolytic potential and cytomembrane penetrability of the BH3 peptide.
Consequently, BH3-AuNp efficiently induced the apoptosis of two most cancers cell traces by an order of magnitude in comparison with BH3. This therapeutic and possible peptide nano-engineering technique will assist peptides overcome the pharmaceutical obstacles, awaken its organic capabilities, and probably revive the analysis about peptide-derived nanomedicine.
 Recombinant Human Hydroxymethylglutaryl-CoA lyase, GST, E.coli-200ug |
|||
| QP6168-ec-200ug | EnQuireBio | 200ug | EUR 760.8 |
 Recombinant Human Hydroxymethylglutaryl-CoA lyase, GST, E.coli-500ug |
|||
| QP6168-ec-500ug | EnQuireBio | 500ug | EUR 1272 |
 Recombinant Human Hydroxymethylglutaryl-CoA lyase, GST, E.coli-50ug |
|||
| QP6168-ec-50ug | EnQuireBio | 50ug | EUR 315.6 |
) Human Hydroxymethylglutaryl-CoA lyase, mitochondrial (HMGCL) |
|||
| 1-CSB-EP010563HU | Cusabio |
|
|
|
Description: Recombinant Human Hydroxymethylglutaryl-CoA lyase, mitochondrial(HMGCL) expressed in E.coli |
|||
 2-hydroxyacyl-CoA lyase 1 Antibody |
|||
| 39416-100ul | SAB | 100ul | EUR 468 |
 Antibody) Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody |
|||
| 20-abx142080 | Abbexa |
|
|
Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody |
|||
| 20-abx007133 | Abbexa |
|
|
Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody |
|||
| 20-abx002856 | Abbexa |
|
|
Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody |
|||
| abx037986-100ug | Abbexa | 100 ug | EUR 469.2 |
Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody |
|||
| abx028671-400ul | Abbexa | 400 ul | EUR 627.6 |
Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody |
|||
| abx028671-80l | Abbexa | 80 µl | EUR 343.2 |
Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody |
|||
| abx030051-400ul | Abbexa | 400 ul | EUR 627.6 |
Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody |
|||
| abx030051-80l | Abbexa | 80 µl | EUR 343.2 |
Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody |
|||
| abx233928-100ug | Abbexa | 100 ug | EUR 577.2 |
Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody |
|||
| 20-abx322761 | Abbexa |
|
|
 anti-2 Hydroxy phytanoyl CoA lyase |
|||
| YF-PA18196 | Abfrontier | 50 ul | EUR 435.6 |
|
Description: Mouse polyclonal to 2 Hydroxy phytanoyl CoA lyase |
|||
anti-2 Hydroxy phytanoyl CoA lyase |
|||
| YF-PA18197 | Abfrontier | 50 ug | EUR 435.6 |
|
Description: Mouse polyclonal to 2 Hydroxy phytanoyl CoA lyase |
|||
) Rhodobacter sphaeroides Modification methylase RsrI (rsrIM) |
|||
| 1-CSB-EP318583RLE | Cusabio |
|
|
|
Description: Recombinant Rhodobacter sphaeroides Modification methylase RsrI(rsrIM) expressed in E.coli |
|||
 Antibody) 2-Hydroxyacyl-CoA Lyase 1 (HACL1) Antibody |
|||
| 20-abx110706 | Abbexa |
|
|
2-Hydroxyacyl-CoA Lyase 1 (HACL1) Antibody |
|||
| abx145222-100ug | Abbexa | 100 ug | EUR 469.2 |
2-Hydroxyacyl-CoA Lyase 1 (HACL1) Antibody |
|||
| abx038305-100ug | Abbexa | 100 ug | EUR 469.2 |
2-Hydroxyacyl-CoA Lyase 1 (HACL1) Antibody |
|||
| abx233746-100ug | Abbexa | 100 ug | EUR 610.8 |
2-Hydroxyacyl-CoA Lyase 1 (HACL1) Antibody |
|||
| 20-abx214192 | Abbexa |
|
|
2-Hydroxyacyl-CoA Lyase 1 (HACL1) Antibody |
|||
| 20-abx214272 | Abbexa |
|
|
 Chicken Hydroxymethylglutaryl- CoA lyase, HMGCL ELISA KIT |
|||
| ELI-27799c | Lifescience Market | 96 Tests | EUR 1113.6 |
 HMGCL 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Human Recombinant Protein |
|||
| PROTP35914 | BosterBio | Regular: 20ug | EUR 380.4 |
|
Description: HMGCL Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 323 amino acids (28-325) and having a molecular mass of 34.2kDa.;HMGCL is fused to a 25 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
|||
 ELISA Kit) Human Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) ELISA Kit |
|||
| abx387826-96tests | Abbexa | 96 tests | EUR 1093.2 |
 Hmgcl ELISA Kit| Rat Hydroxymethylglutaryl-CoA lyase, mitochond |
|||
| EF018825 | Lifescience Market | 96 Tests | EUR 826.8 |
 Hmgcl ELISA Kit| Mouse Hydroxymethylglutaryl-CoA lyase, mitocho |
|||
| EF015212 | Lifescience Market | 96 Tests | EUR 826.8 |
 ELISA Kit) Human 2-Hydroxyacyl-CoA Lyase 1 (HACL1) ELISA Kit |
|||
| abx387730-96tests | Abbexa | 96 tests | EUR 1093.2 |
 Human 2- hydroxyacyl- CoA lyase 1, HACL1 ELISA KIT |
|||
| ELI-27733h | Lifescience Market | 96 Tests | EUR 988.8 |
 Mouse 2- hydroxyacyl- CoA lyase 1, Hacl1 ELISA KIT |
|||
| ELI-27598m | Lifescience Market | 96 Tests | EUR 1038 |
) Argininosuccinate Lyase (Recombinant) |
|||
| 20-abx073248 | Abbexa |
|
|
 HMGCL Human, 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Human Recombinant Protein, Sf9 |
|||
| PROTP35914-1 | BosterBio | Regular: 10ug | EUR 380.4 |
|
Description: HMGCL Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 305 amino acids (28-325 a.a.) and having a molecular mass of 32.5kDa (Molecular size on SDS-PAGE will appear at approximately 28-40kDa). HMGCL is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques. |
|||
 Antibody) 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) Antibody |
|||
| abx038037-100ug | Abbexa | 100 ug | EUR 469.2 |
 ELISA Kit) Rat 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase (HMGCL) ELISA Kit |
|||
| abx391467-96tests | Abbexa | 96 tests | EUR 1093.2 |
 ELISA Kit) Mouse 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase (HMGCL) ELISA Kit |
|||
| abx389578-96tests | Abbexa | 96 tests | EUR 1093.2 |
3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) Antibody |
|||
| 20-abx310139 | Abbexa |
|
|
 Selenocysteine Lyase Recombinant Protein |
|||
| 92-018 | ProSci | 0.05 mg | EUR 852.9 |
|
Description: Selenocysteine Lyase belongs to the class-V pyridoxal-phosphate-dependent aminotransferase family. Selenocysteine Lyase exists as a homodimer in the cytosol. In the brain, Selenocysteine Lyase is as an enzyme that putatively salvages Sec and recycles the selenium for selenoprotein translation. Selenocysteine Lyase catalyzes the decomposition of L-selenocysteine to L-alanine and elemental selenium. Selenocysteine Lyase can be up-regulated In acute glomerulonephritis, it can also be regulated by JUN/AP-1. |
|||
 Recombinant human Selenocysteine lyase |
|||
| P2183 | FN Test | 100ug | Ask for price |
|
Description: Recombinant protein for human Selenocysteine lyase |
|||
 Cystathionine gamma-lyase, Recombinant |
|||
| NATE-1144 | Creative Enzymes | 5mg | EUR 712.8 |
 Cystathionine β-lyase, Recombinant |
|||
| NATE-1146 | Creative Enzymes | 100mg | EUR 712.8 |
 Antibody (HRP)) 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) Antibody (HRP) |
|||
| 20-abx310140 | Abbexa |
|
|
 Antibody (FITC)) 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) Antibody (FITC) |
|||
| 20-abx310141 | Abbexa |
|
|
 Antibody (Biotin)) 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) Antibody (Biotin) |
|||
| 20-abx310142 | Abbexa |
|
|
 ELISA Kit) Human 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) ELISA Kit |
|||
| abx384525-96tests | Abbexa | 96 tests | EUR 1093.2 |
 ELISA Kit) Mouse 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) ELISA Kit |
|||
| abx388460-96tests | Abbexa | 96 tests | EUR 1093.2 |
 Recombinant E.Coli N-Acetylneuraminate Lyase |
|||
| 7-03193 | CHI Scientific | 5µg | Ask for price |
Recombinant E.Coli N-Acetylneuraminate Lyase |
|||
| 7-03194 | CHI Scientific | 20µg | Ask for price |
Recombinant E.Coli N-Acetylneuraminate Lyase |
|||
| 7-03195 | CHI Scientific | 1mg | Ask for price |
 Cystathionine Gamma-Lyase Recombinant Protein |
|||
| 92-113 | ProSci | 0.05 mg | EUR 651.3 |
|
Description: Cystathionine Gamma-Lyase (CTH) belongs to the trans-sulfuration enzymes family. CTH exists as a homotetramer and interacts with CALM in a calcium-dependent manner. CTH breaks down cystathionine into cysteine, ammonia and 2-oxobutanoate. CTH catalyzes the last step in the trans-sulfuration pathway from methionine to cysteine and has broad substrate specificity. Defects in CTH will lead to cystathioninuria, which is an autosomal recessive phenotype characterized by abnormal accumulation of plasma cystathionine. |
|||
) N-acetylneuraminate Pyruvate Lyase (Recombinant) |
|||
| 20-abx073214 | Abbexa |
|
|
) E.Coli N-Acetylneuraminate Lyase (Recombinant) |
|||
| 20-abx073216 | Abbexa |
|
|
) E.coli Deoxyribodipyrimidine photo-lyase (Recombinant) |
|||
| 20-abx073964 | Abbexa |
|
|
 Recombinant human Cystathionine gamma-lyase |
|||
| P1802 | FN Test | 100ug | Ask for price |
|
Description: Recombinant protein for human Cystathionine gamma-lyase |
|||
, Active, Recombinant) Homocysteine ?,?-Lyase (rHCYase), Active, Recombinant |
|||
| P1117-200 | Biovision | EUR 510 | |
) Recombinant Cystathionine Gamma Lyase (CSE) |
|||
| 4-RPB538Hu01 | Cloud-Clone |
|
|
|
Description: Recombinant Human Cystathionine Gamma Lyase expressed in: E.coli |
|||
Recombinant Cystathionine Gamma Lyase (CSE) |
|||
| 4-RPB538Mu01 | Cloud-Clone |
|
|
|
Description: Recombinant Mouse Cystathionine Gamma Lyase expressed in: E.coli |
|||
Recombinant Cystathionine Gamma Lyase (CSE) |
|||
| 4-RPB538Ra01 | Cloud-Clone |
|
|
|
Description: Recombinant Rat Cystathionine Gamma Lyase expressed in: E.coli |
|||
 Acyl-CoA oxidase, Recombinant |
|||
| DIA-292 | Creative Enzymes | 1ku | EUR 324 |
) Methylmalonyl CoA Epimerase (Recombinant) |
|||
| 20-abx073165 | Abbexa |
|
|
 Acyl-CoA synthetase, recombinant |
|||
| NATE-1682 | Creative Enzymes | 1ku | EUR 712.8 |
 Recombinant Human Cystathionine γ-Lyase/CTH |
|||
| CF60-10ug | Novoprotein | 10ug | EUR 175.2 |
|
Description: Supplied as a 0.2 μm filtered solution of 20mM PB,150mM NaCl,20% Glycerol,pH7.4. |
|||
Recombinant Human Cystathionine γ-Lyase/CTH |
|||
| CF60-1mg | Novoprotein | 1mg | EUR 2739.6 |
|
Description: Supplied as a 0.2 μm filtered solution of 20mM PB,150mM NaCl,20% Glycerol,pH7.4. |
|||
Recombinant Human Cystathionine γ-Lyase/CTH |
|||
| CF60-500ug | Novoprotein | 500ug | EUR 1935.6 |
|
Description: Supplied as a 0.2 μm filtered solution of 20mM PB,150mM NaCl,20% Glycerol,pH7.4. |
|||
Recombinant Human Cystathionine γ-Lyase/CTH |
|||
| CF60-50ug | Novoprotein | 50ug | EUR 406.8 |
|
Description: Supplied as a 0.2 μm filtered solution of 20mM PB,150mM NaCl,20% Glycerol,pH7.4. |
|||
 Recombinant Human N-acetylneuraminate Pyruvate Lyase |
|||
| 7-03232 | CHI Scientific | 5µg | Ask for price |
Recombinant Human N-acetylneuraminate Pyruvate Lyase |
|||
| 7-03233 | CHI Scientific | 20µg | Ask for price |
Recombinant Human N-acetylneuraminate Pyruvate Lyase |
|||
| 7-03234 | CHI Scientific | 1mg | Ask for price |
 ATP citrate lyase recombinant monoclonal antibody |
|||
| A5181 | Bimake | 100ul X 3 | EUR 714 |
|
Description: A recombinant monoclonal antibody from rabbit against human ATP citrate lyase for WB,ELISA |
|||
 L-Methionine ?-Lyase, Pseudomonas putida recombinant |
|||
| 7848-100 | Biovision | EUR 189.6 | |
L-Methionine ?-Lyase, Pseudomonas putida recombinant |
|||
| 7848-500 | Biovision | EUR 464.4 | |
 Hyaluronate Lyase from Streptococcus pyogenes, recombinant |
|||
| NATE-0346 | Creative Enzymes | 10mg | EUR 440.4 |
 ADSL Adenylosuccinate Lyase Human Recombinant Protein |
|||
| PROTP30566 | BosterBio | Regular: 20ug | EUR 380.4 |
|
Description: ADSL Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 520 amino acids (1-484) and having a molecular mass of 59kDa.;ADSL is fused to a 36 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
|||
 ASL Argininosuccinate Lyase Human Recombinant Protein |
|||
| PROTP04424 | BosterBio | Regular: 20ug | EUR 380.4 |
|
Description: ASL Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 484 amino acids (1-464) and having a molecular mass of 53.8kDa.;ASL is fused to a 20 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
|||
 Argininosuccinate Lyase Antibody |
|||
| DF13850 | Affbiotech | 100ul | EUR 420 |
 Adenylosuccinate Lyase Antibody |
|||
| DF13918 | Affbiotech | 100ul | EUR 420 |
) Alginate lyase (algL) |
|||
| 1-CSB-EP524422DPX | Cusabio |
|
|
|
Description: Recombinant Alginate lyase(algL) expressed in E.coli |
|||
 Argininosuccinate Lyase antibody |
|||
| 22249-100ul | SAB | 100ul | EUR 468 |
Argininosuccinate Lyase antibody |
|||
| 22612-100ul | SAB | 100ul | EUR 468 |
 Selenocysteine Lyase Antibody |
|||
| 20-abx115419 | Abbexa |
|
|
 anti-Adenylosuccinate Lyase |
|||
| YF-PA10105 | Abfrontier | 50 ug | EUR 435.6 |
|
Description: Mouse polyclonal to Adenylosuccinate Lyase |
|||
anti-Adenylosuccinate Lyase |
|||
| YF-PA10106 | Abfrontier | 100 ug | EUR 483.6 |
|
Description: Rabbit polyclonal to Adenylosuccinate Lyase |
|||
 anti-Argininosuccinate Lyase |
|||
| YF-PA10364 | Abfrontier | 50 ug | EUR 435.6 |
|
Description: Mouse polyclonal to Argininosuccinate Lyase |
|||
anti-Argininosuccinate Lyase |
|||
| YF-PA10365 | Abfrontier | 100 ug | EUR 483.6 |
|
Description: Rabbit polyclonal to Argininosuccinate Lyase |
|||
 Recombinant Human Methylmalonyl CoA Epimerase |
|||
| 7-02737 | CHI Scientific | 5µg | Ask for price |
Recombinant Human Methylmalonyl CoA Epimerase |
|||
| 7-02738 | CHI Scientific | 20µg | Ask for price |
